Due to its major catabolic activity for the endocannabinoid anandamide (AEA), testing of FAAH inhibitors is important for drug development for diverse diseases, including depression, anxiety, aggressive behaviour, borderline personality disorder, substance use disorders and inflammatory bowel disease [10,11,12,13]. Here, FAAH is linked to depressive disorder.